A citation-based method for searching scientific literature

Philippe Armand, Andreas Engert, Anas Younes, Michelle Fanale, Armando Santoro, Pier Luigi Zinzani, John M Timmerman, Graham P Collins, Radhakrishnan Ramchandren, Jonathon B Cohen, Jan Paul De Boer, John Kuruvilla, Kerry J Savage, Marek Trneny, Margaret A Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M Ansell. J Clin Oncol 2018
Times Cited: 285







List of co-cited articles
703 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. J Clin Oncol 2017
528
50

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
40

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla,[...]. Lancet Oncol 2016
557
38

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. Blood 2019
106
36

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen S Snyder, Alejandro D Ricart, Arun Balakumaran, Shelonitda Rose,[...]. J Clin Oncol 2016
415
31

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Anas Younes, Ajay K Gopal, Scott E Smith, Stephen M Ansell, Joseph D Rosenblatt, Kerry J Savage, Radhakrishnan Ramchandren, Nancy L Bartlett, Bruce D Cheson, Sven de Vos,[...]. J Clin Oncol 2012
908
27

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Margaretha G M Roemer, Ranjana H Advani, Azra H Ligon, Yasodha Natkunam, Robert A Redd, Heather Homer, Courtney F Connelly, Heather H Sun, Sarah E Daadi, Gordon J Freeman,[...]. J Clin Oncol 2016
404
25

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Alex F Herrera, Alison J Moskowitz, Nancy L Bartlett, Julie M Vose, Radhakrishnan Ramchandren, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H Moskowitz, Keenan Fenton,[...]. Blood 2018
182
25

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
Radhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, Marek Trněný, Tatyana A Feldman, Hun Ju Lee, Mariano Provencio, Christian Sillaber, Jonathon B Cohen, Kerry J Savage,[...]. J Clin Oncol 2019
78
29

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, Scott J Rodig, Przemyslaw Juszczynski, Treeve Currie, Evan O'Donnell, Bjoern Chapuy, Kunihiko Takeyama, Donna Neuberg, Todd R Golub,[...]. Blood 2010
757
21

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Joseph M Connors, Wojciech Jurczak, David J Straus, Stephen M Ansell, Won S Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi,[...]. N Engl J Med 2018
305
20

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
18

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.
Bruce D Cheson, Stephen Ansell, Larry Schwartz, Leo I Gordon, Ranjana Advani, Heather A Jacene, Axel Hoos, Sally F Barrington, Philippe Armand. Blood 2016
175
17

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Yuankai Shi, Hang Su, Yongping Song, Wenqi Jiang, Xiuhua Sun, Wenbin Qian, Wei Zhang, Yuhuan Gao, Zhengming Jin, Jianfeng Zhou,[...]. Lancet Haematol 2019
76
22

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Margaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, Christine J Pak, Sara Abdelrahman, Jing Ouyang, Stephanie Sasse, Anas Younes, Michelle Fanale, Armando Santoro,[...]. J Clin Oncol 2018
141
16

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Philippe Armand, Yi-Bin Chen, Robert A Redd, Robin M Joyce, Jad Bsat, Erin Jeter, Reid W Merryman, Kimberly C Coleman, Parastoo B Dahi, Yago Nieto,[...]. Blood 2019
55
29

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Reid W Merryman, Haesook T Kim, Pier Luigi Zinzani, Carmelo Carlo-Stella, Stephen M Ansell, Miguel-Angel Perales, Abraham Avigdor, Ahmad S Halwani, Roch Houot, Tony Marchand,[...]. Blood 2017
145
16

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Norbert Schmitz, Beate Pfistner, Michael Sextro, Markus Sieber, Angelo M Carella, Matthias Haenel, Friederike Boissevain, Reinhart Zschaber, Peter Müller, Hartmut Kirchner,[...]. Lancet 2002
709
16

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
591
15

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Christopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G M Roemer, Edward C Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J Freeman, Donna Neuberg,[...]. Blood 2017
145
14

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Christian Steidl, Sohrab P Shah, Bruce W Woolcock, Lixin Rui, Masahiro Kawahara, Pedro Farinha, Nathalie A Johnson, Yongjun Zhao, Adele Telenius, Susana Ben Neriah,[...]. Nature 2011
384
14

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Craig H Moskowitz, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H Abidi, Andy I Chen, Patrick Stiff, Alessandro M Gianni, Angelo Carella,[...]. Lancet 2015
373
14

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy,[...]. J Clin Oncol 2019
124
13

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
13

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Michael R Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A Shipp. Clin Cancer Res 2012
420
13

Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Paul J Bröckelmann, Helen Goergen, Ulrich Keller, Julia Meissner, Rainer Ordemann, Teresa V Halbsguth, Stephanie Sasse, Martin Sökler, Andrea Kerkhoff, Stephan Mathas,[...]. JAMA Oncol 2020
28
46

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Robert Chen, Ajay K Gopal, Scott E Smith, Stephen M Ansell, Joseph D Rosenblatt, Kerry J Savage, Joseph M Connors, Andreas Engert, Emily K Larsen, Dirk Huebner,[...]. Blood 2016
201
12

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Benjamin J Chen, Bjoern Chapuy, Jing Ouyang, Heather H Sun, Margaretha G M Roemer, Mina L Xu, Hongbo Yu, Christopher D M Fletcher, Gordon J Freeman, Margaret A Shipp,[...]. Clin Cancer Res 2013
528
12

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Craig H Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H Abidi, Andy I Chen, Patrick Stiff, Simonetta Viviani,[...]. Blood 2018
73
16

Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Jing Nie, Chunmeng Wang, Yang Liu, Qingming Yang, Qian Mei, Liang Dong, Xiang Li, Jiejie Liu, Wenjing Ku, Yan Zhang,[...]. J Clin Oncol 2019
56
21

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Peter Johnson, Massimo Federico, Amy Kirkwood, Alexander Fosså, Leanne Berkahn, Angelo Carella, Francesco d'Amore, Gunilla Enblad, Antonella Franceschetto, Michael Fulham,[...]. N Engl J Med 2016
366
11

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
972
11

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Philippe Armand, Scott Rodig, Vladimir Melnichenko, Catherine Thieblemont, Kamal Bouabdallah, Gayane Tumyan, Muhit Özcan, Sergio Portino, Laura Fogliatto, Maria D Caballero,[...]. J Clin Oncol 2019
80
13

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Yuqin Song, Quanli Gao, Huilai Zhang, Lei Fan, Jianfeng Zhou, Dehui Zou, Wei Li, Haiyan Yang, Ting Liu, Quanshun Wang,[...]. Leukemia 2020
35
31

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Margaretha G M Roemer, Ranjana H Advani, Robert A Redd, Geraldine S Pinkus, Yasodha Natkunam, Azra H Ligon, Courtney F Connelly, Christine J Pak, Christopher D Carey, Sarah E Daadi,[...]. Cancer Immunol Res 2016
97
10

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
D C Linch, D Winfield, A H Goldstone, D Moir, B Hancock, A McMillan, R Chopra, D Milligan, G V Hudson. Lancet 1993
784
10

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Ann S LaCasce, R Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M Ansell, Howland E Crosswell, Miguel Islas-Ohlmayer, Caroline Behler,[...]. Blood 2018
102
10

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Charles Herbaux, Jordan Gauthier, Pauline Brice, Elodie Drumez, Loic Ysebaert, Hélène Doyen, Luc Fornecker, Krimo Bouabdallah, Guillaume Manson, Hervé Ghesquières,[...]. Blood 2017
138
10

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, Jonathon B Cohen, Michael J Robertson, Kevin A David, Ranjana H Advani, Timothy S Fenske, Stefan K Barta, Neil D Palmisiano,[...]. Lancet Haematol 2020
25
40

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.
Cédric Rossi, Julia Gilhodes, Marie Maerevoet, Charles Herbaux, Franck Morschhauser, Pauline Brice, Sylvain Garciaz, Cécile Borel, Loïc Ysebaert, Lucie Obéric,[...]. Am J Hematol 2018
49
18

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
Yvette L Kasamon, R Angelo de Claro, Yaping Wang, Yuan Li Shen, Ann T Farrell, Richard Pazdur. Oncologist 2017
81
11

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Bradley M Haverkos, Diana Abbott, Mehdi Hamadani, Philippe Armand, Mary E Flowers, Reid Merryman, Manali Kamdar, Abraham Sebastian Kanate, Ayman Saad, Amitkumar Mehta,[...]. Blood 2017
153
9

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Lakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G M Roemer, Bjoern Chapuy, Philippe Armand, Scott J Rodig, Margaret A Shipp. Blood 2017
207
9

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Carlos A Ramos, Natalie S Grover, Anne W Beaven, Premal D Lulla, Meng-Fen Wu, Anastasia Ivanova, Tao Wang, Thomas C Shea, Cliona M Rooney, Christopher Dittus,[...]. J Clin Oncol 2020
43
20

Revised response criteria for malignant lymphoma.
Bruce D Cheson, Beate Pfistner, Malik E Juweid, Randy D Gascoyne, Lena Specht, Sandra J Horning, Bertrand Coiffier, Richard I Fisher, Anton Hagenbeek, Emanuele Zucca,[...]. J Clin Oncol 2007
8

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
8

Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.
Jonathan Reichel, Amy Chadburn, Paul G Rubinstein, Lisa Giulino-Roth, Wayne Tam, Yifang Liu, Rafael Gaiolla, Kenneth Eng, Joshua Brody, Giorgio Inghirami,[...]. Blood 2015
173
8

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
Christian Steidl, Tang Lee, Sohrab P Shah, Pedro Farinha, Guangming Han, Tarun Nayar, Allen Delaney, Steven J Jones, Javeed Iqbal, Dennis D Weisenburger,[...]. N Engl J Med 2010
845
8


Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford, Tim Illidge, Nicholas Counsell, Barry Hancock, Ruth Pettengell, Peter Johnson, Jennie Wimperis, Dominic Culligan, Bilyana Popova, Paul Smith,[...]. N Engl J Med 2015
371
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.